

# **ENRIQUE MADRUGA MAYORDOMO**

Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC). Madrid. Spain.

Tel: +56 9 726 736 98 (Chile) // +34 671540407 (Spain)

ORCID: 0000-0002-7012-9737 email: [enrique.madruga@cib.csic.es](mailto:enrique.madruga@cib.csic.es)

## **Education**

1. Pharmacy Degree (2014-2019). Universidad de Salamanca. Best Academic Record by Castile and Leon Pharmacy Academy and Best Academic Record by the University of Salamanca
2. Drug Discovery Master's Degree (2019-2020). Universidad Complutense de Madrid.

## **Professional experience**

1. Grant-assisted student at Centro de Investigación del Cáncer. 2019.
2. Research assistant at Centro de Investigaciones Biológicas Margarita Salas. 2020
3. JAEIntro grant-assisted student at Centro de Investigaciones Biológicas Margarita Salas. 2020-2021.
4. Research assistant at Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED). 2021
5. FPI grant-assisted researcher at Centro de Investigaciones Biológicas Margarita Salas 2021.
6. FPU grant-assisted researcher at Centro de Investigaciones Biológicas Margarita Salas 2021-currently.

## **Scientific publications**

1. Madruga E, Maestro I, Martínez A. Mitophagy Modulation, a New Player in the Race against ALS. *Int J Mol Sci*. 2021;22(2):740.
2. Méndez-Líter JA, Pozo-Rodríguez A, Madruga E, et al. Glycosylation of Epigallocatechin Gallate by Engineered Glycoside Hydrolases from *Talaromyces amestolkiae*: Potential Antiproliferative and Neuroprotective Effect of These Molecules. *Antioxidants (Basel)*. 2022;11(7):1325.
3. Maestro I, Madruga E, Boya P, Martínez A. Identification of a new structural family of SGK1 inhibitors as potential neuroprotective agents. *J Enzyme Inhib Med Chem*. 2023;38(1):2153841.
4. Ginex T, Madruga E, Martinez A, Gil C. MBC and ECBL libraries: outstanding tools for drug discovery. *Front Pharmacol*. 2023;14:1244317.

## **Participation in scientific events**

1. Machine-learning enhanced virtual screening to find new GSK-3 $\beta$  inhibitors (Oral communication). VIII SEQT Summer School. Santiago de Compostela. Spain. 2023.
2. Discovery of new SGK1 inhibitors using a ligand and target mixed virtual screening methodology (Oral communication). XIII Spanish Drug Discovery Network. Madrid. Spain. 2021.